ClinicalTrials.gg
CompletedNCT00603447Updated May 30, 2017Results posted

Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

A Phase 1 interventional study of Carfilzomib and Lenalidomide in Relapsed Multiple Myeloma, sponsored by Amgen. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
31st of 113
84 · median 54
Started
2008
with 1 other
Phase 1
17 of 113
2 open now
Registered
5th of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 31st largest by enrollment, is one of 2 that started in 2008, is one of 17 in phase 1, and was the 5th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

To evaluate the safety and maximum tolerated dose (MTD) of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma

03

Conditions studied

  • Relapsed Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Disease related:

  1. Symptomatic multiple myeloma
  2. or progressive disease after at least one but no more than three prior therapeutic treatments or regimens for multiple myeloma
  3. Prior therapeutic treatment regimens may have included bortezomib, lenalidomide, and/or thalidomide, among other agents.
  4. If previously treated with lenalidomide or bortezomib, the subject must not have progressed during the first 3 months of treatment with the drug and must not have discontinued treatment due to lenalidomide intolerance (bortezomib intolerant subjects may enroll).
  5. , as indicated by one or more of the following:

    • Serum M-protein ≥ 0.5 g/dL
    • Urine Bence-Jones protein ≥ 200 mg/24 h
    • If Serum Protein Electrophoresis is felt to be unreliable for routine M-protein measurement (particularly for patients with Immunoglobulin (Ig)A multiple myeloma), then quantitative immunoglobulin levels can be accepted.
  6. Prior to enrollment, sites must provide evidence of myeloma progression/relapse, with start and stop dates of the most recent treatment regimen, as well as best tumor response to all prior treatment regimens.

    Demographic

  7. Males and females ≥ 18 years of age
  8. of more than three months
  9. (ECOG) Performance Status 0-2

    Laboratory

  10. Adequate hepatic function, with \< 2 times the (ULN) and (ALT) \< 3 times ULN
  11. (ANC) ≥ 1,000/mm³, ≥ 8 gm/dL, count ≥ 50,000/ mm³ (≥ 30 × 10\^9/L if myeloma involvement in the bone marrow is > 50%)

    • Screening ANC should be independent of granulocyte- and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for at least 2 weeks.
    • Subjects may receive red blood cell (RBC) or platelet transfusions, if clinically indicated, in accordance with institutional guidelines
    • Screening platelet count should be independent of platelet transfusions for at least 2 weeks
  12. Calculated or measured of ≥ 50 mL/minute, calculated using the formula of Cockcroft and Gault [(140 - Age) x Mass (kg) / (72 x creatinine mg/dL)]; multiply result by 0.85 (if female). Other generally accepted calculation methods can be substituted.

    Ethical/Other

  13. Written in accordance with federal, local, and institutional guidelines
  14. Females of (FCBP) must agree to ongoing pregnancy testing
  15. FCBP* must have a negative serum or urine pregnancy test, with a sensitivity of at least 50 mIU/mL within 10-14 days (US/RevAssist®) or 25 mIU/mL within 7-14 days (Canada/RevAidSM), prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or to use two methods of reliable , including at least one highly effective method AND one additional effective method of birth control (contraception) AT THE SAME TIME, beginning 4 weeks prior to initiating treatment with lenalidomide, during therapy, during therapy delay, and continuing for 4 weeks following discontinuation of lenalidomide therapy. If a hormonal method (birth control pills, injections, patch or implants) or intrauterine device (IUD) is not medically possible for the subject, the subject may use another highly effective method or two barrier methods AT THE SAME TIME.
  16. Male subjects must agree to NEVER have unprotected sexual contact with a female who can become pregnant and must agree to either completely abstain from sexual contact with females who are pregnant or are able to become pregnant, or he must use a latex condom EVERY TIME he engages in any sexual contact with females who are pregnant or may become pregnant while he is taking lenalidomide and for 4 weeks after he stops taking the drug, even if he has had a successful vasectomy. The subject must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks FOR ANY REASON, that his sexual partner may be pregnant.
  17. Male subjects cannot donate semen or sperm while taking lenalidomide.
  18. All study participants must be registered into the mandatory RevAssist (US) or RevAid (Canada) programs and be willing and able to comply with the requirements of Rev Assist/RevAid
  19. Subjects must adhere to the study visit schedule and other protocol requirements and receive outpatient treatment and laboratory monitoring at the institute that administers the drug
  20. Subjects must agree to take enteric-coated aspirin 81-325 mg orally daily, or if history of prior thrombotic disease or allergy to aspirin, must be fully anticoagulated with warfarin ( 2-3) or be treated with full-dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism.

Exclusion criteria

Exclusion Criteria:

Disease related

  1. Subjects with non-secretory or hyposecretory multiple myeloma, defined as \< 0.5 g/dL M-protein in serum, \< 200 mg/24 hr Bence Jones protein in urine, or disease only measured by serum free light chain (FLC)
  2. Subjects who never achieved at least a durable minimal response (MR, ≥ 25% reduction in M-protein for at least 6 weeks) on any prior therapy
  3. therapy in a dose equivalent to dexamethasone ≥ 4 mg/day or prednisone ≥ 20 mg/day within 3 weeks prior to first dose
  4. Use of any other experimental drug or therapy within 28 days of baseline
  5. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  6. Plasma cell leukemia
  7. Waldenström's macroglobulinemia
  8. Chemotherapy with approved or investigative anticancer therapeutics, including steroid therapy dose as defined above, within 3 weeks prior to first dose
  9. Radiation therapy or immunotherapy within 4 weeks prior to first dose; localized radiation therapy within 1 week prior to first dose
  10. Planned radiation therapy that occurs after the start of treatment
  11. Participation in an therapeutic study within 3 weeks or within 5 drug half-lives (t1/2) prior to first dose, whichever time is greater.

    Concurrent conditions

  12. Pregnant or lactating females
  13. History of allergy to boron or mannitol
  14. Major surgery within 3 weeks prior to first dose
  15. Congestive heart failure ( class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention or myocardial infarction in the previous six months
  16. Uncontrolled hypertension
  17. Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose
  18. Known or suspected (HIV) infection, known HIV seropositivity, or active hepatitis A, B, or C infection
  19. Non-hematologic within the past three years except

    1. adequately treated basal cell or squamous cell skin cancer,
    2. carcinoma in situ of the cervix, or
    3. prostate cancer \< Gleason Grade 6 with stable prostate specific antigen (PSA) levels
  20. Serious psychiatric or medical conditions that could interfere with treatment
  21. Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment
  22. to any of the required concomitant drugs, including proton-pump inhibitor (e.g., lansoprazole), enteric-coated aspirin or other anticoagulant, or if a history of prior thrombotic disease, warfarin or low molecular weight heparin
  23. Subjects in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g., due to pre-existing pulmonary, cardiac, or renal impairment
  24. Subjects with known or suspected amyloidosis
  25. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis
  26. Prior carfilzomib treatment
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Carfilzomib + Lenalidomide + Dexamethasone

    Treatment during Cycles 1 through 12 consisted of carfilzomib (15, 20, or 20/27 mg/m²) on Days 1, 2, 8, 9, 15, and 16; lenalidomide (10, 15, 20, or 25 mg) on Days 1 to 21; and low-dose dexamethasone (40 mg) given 30 minutes to 4 hours before the carfilzomib dose on Days 1, 8, and 15, as well as on Day 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.

    Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone

Interventions

  • Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.

    Also known as: Kyprolis®

  • Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.

    Also known as: REVLIMID®

  • Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Treatment-related are those AEs with possible or probable relationship to carfilzomib, lenalidomide or dexamethasone as assessed by the Investigator. The severity of each adverse event was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0, per the following: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Serious adverse events were defined as AEs meeting one of the following: death, life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in the offspring of an exposed participant, important medical events that may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above, or pregnancy or suspected pregnancy.

    Time frame: From the first dose of study drug until 30 days after the last dose; 1 to 52 months, with an average of 12 months.

  2. Number of Participants With Dose-limiting Toxicities

    Dose-limiting toxicity was defined as any of the following events assessed as related to carfilzomib, lenalidomide, or dexamethasone: Nonhematologic * ≥ Grade 2 neuropathy with pain * ≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, diarrhea, hyperglycemia due to dexamethasone, and rash due to lenalidomide) * ≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal supportive therapy * ≥ Grade 4 fatigue persisting \> 7 days * Treatment delay for toxicity \> 21 days Hematologic * Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 500/mm³) \> 7 days * Febrile neutropenia (ANC \< 1,000/mm³ with fever ≥ 38.3ºC) * Grade 4 thrombocytopenia (platelets \< 25,000/mm³) for \> 7 days despite holding treatment, or Grade 3 or 4 thrombocytopenia associated with bleeding * Treatment delay for toxicity \> 21 days. The maximum-tolerated dose was defined as the dose level below which a drug-related DLT was observed in ≥ 33% of participants in a cohort.

    Time frame: Cycle 1, 28 days

07

Results

Posted Jun 3, 2015

Participant flow

This was an open-label study of carfilzomib (CFZ) given in combination with lenalidomide (LEN) and low-dose dexamethasone (DEX) in patients with relapsed multiple myeloma. The study consisted of a dose-escalation portion and an expansion portion. Participants were treated until disease progression (PD) or unacceptable toxicity.

Participant flow — Overall Study
Milestone1: CFZ 15 mg/m² + LEN 10 mg2: CFZ 15 mg/m² + LEN 15 mg3: CFZ 15 mg/m² + LEN 20 mg4: CFZ 20 mg/m² + LEN 20 mg5: CFZ 20 mg/m² + LEN 25 mg6: CFZ 20/27 mg/m² + LEN 25 mg7: CFZ 20/27 mg/m² + LEN 25 mg
Started66866844
Completed63641620
Not completed03225224
Withdrew: Adverse event01121210
Withdrew: Other00103013
Withdrew: Withdrew consent0200101

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

Treatment-related are those AEs with possible or probable relationship to carfilzomib, lenalidomide or dexamethasone as assessed by the Investigator. The severity of each adverse event was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0, per the following: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Serious adverse events were defined as AEs meeting one of the following: death, life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in the offspring of an exposed participant, important medical events that may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above, or pregnancy or suspected pregnancy.

Time frame:
From the first dose of study drug until 30 days after the last dose; 1 to 52 months, with an average of 12 months.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participants1: CFZ 15 mg/m² + LEN 10 mg2: CFZ 15 mg/m² + LEN 15 mg3: CFZ 15 mg/m² + LEN 20 mg4: CFZ 20 mg/m² + LEN 20 mg5: CFZ 20 mg/m² + LEN 25 mg6: CFZ 20/27 mg/m² + LEN 25 mg7: CFZ 20/27 mg/m² + LEN 25 mg
Any adverse event66866844
Treatment-related adverse event45846843
Grade 3 or higher adverse event56866841
Treatment-related Grade 3 or higher adverse event14746838
Serious adverse event33443622
AE leading to discontinuation of any study drug11342318
AE leading to discontinuation of carfilzomib0012119
Deaths within 30 days of last dose of study drug0000003
PrimaryNumber of Participants With Dose-limiting Toxicities

Dose-limiting toxicity was defined as any of the following events assessed as related to carfilzomib, lenalidomide, or dexamethasone: Nonhematologic * ≥ Grade 2 neuropathy with pain * ≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, diarrhea, hyperglycemia due to dexamethasone, and rash due to lenalidomide) * ≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal supportive therapy * ≥ Grade 4 fatigue persisting \> 7 days * Treatment delay for toxicity \> 21 days Hematologic * Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 500/mm³) \> 7 days * Febrile neutropenia (ANC \< 1,000/mm³ with fever ≥ 38.3ºC) * Grade 4 thrombocytopenia (platelets \< 25,000/mm³) for \> 7 days despite holding treatment, or Grade 3 or 4 thrombocytopenia associated with bleeding * Treatment delay for toxicity \> 21 days. The maximum-tolerated dose was defined as the dose level below which a drug-related DLT was observed in ≥ 33% of participants in a cohort.

Time frame:
Cycle 1, 28 days
Reported as:
Number · participants
Number of Participants With Dose-limiting Toxicities
participants1: CFZ 15 mg/m² + LEN 10 mg2: CFZ 15 mg/m² + LEN 15 mg3: CFZ 15 mg/m² + LEN 20 mg4: CFZ 20 mg/m² + LEN 20 mg5: CFZ 20 mg/m² + LEN 25 mg6: CFZ 20/27 mg/m² + LEN 25 mg
Number of Participants With Dose-limiting Toxicities000001

Adverse events

Collected over From the first dose of study drug until 30 days after the last dose; 1 to 52 months, with an average of 12 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1: CFZ 15 mg/m² + LEN 10 mg—3/6 (50%)6/6 (100%)
2: CFZ 15 mg/m² + LEN 15 mg—3/6 (50%)6/6 (100%)
3: CFZ 15 mg/m² + LEN 20 mg—4/8 (50%)8/8 (100%)
4: CFZ 20 mg/m² + LEN 20 mg—4/6 (66.7%)6/6 (100%)
5: CFZ 20 mg/m² + LEN 25 mg—3/6 (50%)6/6 (100%)
6: CFZ 20/27 mg/m² + LEN 25 mg—6/8 (75%)8/8 (100%)
7: CFZ 20/27 mg/m² + LEN 25 mg—22/44 (50%)42/44 (95.5%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
Event1: CFZ 15 mg/m² + LEN 10 mg2: CFZ 15 mg/m² + LEN 15 mg3: CFZ 15 mg/m² + LEN 20 mg4: CFZ 20 mg/m² + LEN 20 mg5: CFZ 20 mg/m² + LEN 25 mg6: CFZ 20/27 mg/m² + LEN 25 mg7: CFZ 20/27 mg/m² + LEN 25 mg
Disease progressionGeneral disorders2/60/60/80/60/60/81/44
PyrexiaGeneral disorders0/60/62/80/60/60/81/44
InfluenzaInfections and infestations0/60/60/81/60/62/80/44
PneumoniaInfections and infestations0/61/60/81/60/62/83/44
BradycardiaCardiac disorders0/60/60/80/61/60/80/44
Sick sinus syndromeCardiac disorders0/61/60/80/60/60/80/44
DiarrhoeaGastrointestinal disorders0/60/60/81/60/60/80/44
Small intestinal obstructionGastrointestinal disorders0/60/60/80/61/60/80/44
PainGeneral disorders0/61/60/80/60/60/80/44
CellulitisInfections and infestations1/60/60/80/60/60/80/44
Most frequent other events
Showing 10 of 272
Most frequent other events
Event1: CFZ 15 mg/m² + LEN 10 mg2: CFZ 15 mg/m² + LEN 15 mg3: CFZ 15 mg/m² + LEN 20 mg4: CFZ 20 mg/m² + LEN 20 mg5: CFZ 20 mg/m² + LEN 25 mg6: CFZ 20/27 mg/m² + LEN 25 mg7: CFZ 20/27 mg/m² + LEN 25 mg
NeutropeniaBlood and lymphatic system disorders4/64/64/82/65/63/816/44
CoughRespiratory, thoracic and mediastinal disorders1/65/63/82/63/64/817/44
AnaemiaBlood and lymphatic system disorders2/62/66/82/63/63/814/44
FatigueGeneral disorders3/64/65/83/64/66/830/44
DiarrhoeaGastrointestinal disorders3/63/63/83/64/64/826/44
Oedema peripheralGeneral disorders0/64/62/80/63/62/817/44
Muscle spasmsMusculoskeletal and connective tissue disorders1/64/64/81/61/63/817/44
LymphopeniaBlood and lymphatic system disorders1/63/62/81/60/65/822/44
PyrexiaGeneral disorders0/61/65/83/61/64/819/44
LeukopeniaBlood and lymphatic system disorders0/63/61/81/61/62/89/44

Baseline characteristics

Age, Continuous
Age, Continuous(years)1: CFZ 15 mg/m² + LEN 10 mg2: CFZ 15 mg/m² + LEN 15 mg3: CFZ 15 mg/m² + LEN 20 mg4: CFZ 20 mg/m² + LEN 20 mg5: CFZ 20 mg/m² + LEN 25 mg6: CFZ 20/27 mg/m² + LEN 25 mg7: CFZ 20/27 mg/m² + LEN 25 mgTotal
Mean64.7 ± 6.6564.2 ± 12.1155.4 ± 7.7461.7 ± 6.6857.7 ± 9.3165.4 ± 7.8562.4 ± 10.7561.9 ± 9.86
Sex: Female, Male
Sex: Female, Male(Participants)1: CFZ 15 mg/m² + LEN 10 mg2: CFZ 15 mg/m² + LEN 15 mg3: CFZ 15 mg/m² + LEN 20 mg4: CFZ 20 mg/m² + LEN 20 mg5: CFZ 20 mg/m² + LEN 25 mg6: CFZ 20/27 mg/m² + LEN 25 mg7: CFZ 20/27 mg/m² + LEN 25 mgTotal
Female1434331836
Male5252352648
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)1: CFZ 15 mg/m² + LEN 10 mg2: CFZ 15 mg/m² + LEN 15 mg3: CFZ 15 mg/m² + LEN 20 mg4: CFZ 20 mg/m² + LEN 20 mg5: CFZ 20 mg/m² + LEN 25 mg6: CFZ 20/27 mg/m² + LEN 25 mg7: CFZ 20/27 mg/m² + LEN 25 mgTotal
African American02121039
Asian/Pacific Islander01000023
Caucasian6372573464
Hispanic00020147
Other00000011
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)1: CFZ 15 mg/m² + LEN 10 mg2: CFZ 15 mg/m² + LEN 15 mg3: CFZ 15 mg/m² + LEN 20 mg4: CFZ 20 mg/m² + LEN 20 mg5: CFZ 20 mg/m² + LEN 25 mg6: CFZ 20/27 mg/m² + LEN 25 mg7: CFZ 20/27 mg/m² + LEN 25 mgTotal
0 (Fully active)2031222333
1 (Restrictive but ambulatory)4555461746
2 (Ambulatory but unable to work)01000045
Time Since Diagnosis
Time Since Diagnosis(years)1: CFZ 15 mg/m² + LEN 10 mg2: CFZ 15 mg/m² + LEN 15 mg3: CFZ 15 mg/m² + LEN 20 mg4: CFZ 20 mg/m² + LEN 20 mg5: CFZ 20 mg/m² + LEN 25 mg6: CFZ 20/27 mg/m² + LEN 25 mg7: CFZ 20/27 mg/m² + LEN 25 mgTotal
Median3.3 (2 to 4)2.4 (2 to 5)3.9 (2 to 15)2.8 (0 to 9)3.5 (1 to 22)4.3 (1 to 12)2.8 (0 to 16)3.1 (0 to 22)
08

Study locations

12 sites
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Cornell University
    New York, New York 10021, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Fred Hutch Cancer Research Center
    Seattle, Washington 98103-1204, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
09

References and documents

Publications

  • Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31;122(18):3122-8. doi: 10.1182/blood-2013-07-511170. Epub 2013 Sep 6. PubMed 24014245 ↗
  • Niesvizky R, Martin TG 3rd, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15;19(8):2248-56. doi: 10.1158/1078-0432.CCR-12-3352. Epub 2013 Feb 27. PubMed 23447001 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of May 2013 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2008
First posted
Jan 29, 2008
Start
May 2008
Primary completionActual
May 2013
CompletionActual
Jan 2016
Results first posted
Jun 3, 2015
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00603447
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 29, 2008
Start date
May 2008
Primary completion
May 2013
Completion
Jan 2016
Results posted
Jun 3, 2015
Last update
May 30, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion